More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives (see "AZ's Mallon to Lead Ironwood; Hecht to Helm Spinout"; "Immunocore Taps MedImmune's Jallal as CEO").
Here's BioCentury Extra's roundup in alphabetical order:
Cancer company Adastra Pharmaceuticals Inc. (Princeton, N.J.), which changed its name from Tragara Pharmaceuticals Inc. on Jan. 3, hired Scott Megaffin as CEO and a director. Megaffin replaces Tom Estok, who remains a director. Megaffin was president of Churchill Pharmaceuticals LLC (King of Prussia, Pa.).
Metabolic disease company Allena Pharmaceuticals Inc. (NASDAQ:ALNA) will promote President and COO Louis Brenner to CEO, effective Feb. 1. He succeeds co-founder and CEO Alexey Margolin,